In our study, we tried to understand why we have some patients who have a negative liquid biopsy but still have visible metastatic disease on imaging. To do that, we did a retrospective analysis of 1019 patients who had both liquid biopsy and CT scans at baseline. And we derived imaging metrics from these patients, which were the total tumor volume, the lesion count, and the tumor volume metastatic distribution by organ...
In our study, we tried to understand why we have some patients who have a negative liquid biopsy but still have visible metastatic disease on imaging. To do that, we did a retrospective analysis of 1019 patients who had both liquid biopsy and CT scans at baseline. And we derived imaging metrics from these patients, which were the total tumor volume, the lesion count, and the tumor volume metastatic distribution by organ. So what is interesting in our study is that we found almost 29% of patients who had a negative liquid biopsy while having active metastatic disease on imaging. And we annotated 55,000 metastatic lesions, and we found that these variables, the total tumor volume, the lesion count, and the metastatic locations, which were the liver, the lymph nodes, and the bones, were positively associated with ctDNA detectability independently of each other.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.